Literature DB >> 25895867

Synthetic high-density lipoprotein-like nanoparticles as cancer therapy.

Kaylin M McMahon1, Linda Foit, Nicholas L Angeloni, Francis J Giles, Leo I Gordon, C Shad Thaxton.   

Abstract

High-density lipoproteins (HDL) are diverse natural nanoparticles that carry cholesterol and are best known for the role that they play in cardiovascular disease. However, due to their unique targeting capabilities, diverse molecular cargo, and natural functions beyond cholesterol transport, it is becoming increasingly appreciated that HDLs are critical to cancer development and progression. Accordingly, this chapter highlights ongoing research focused on the connections between HDL and cancer in order to design new drugs and targeted drug delivery vehicles. Research is focused on synthesizing biomimetic HDL-like nanoparticles (NP) that can be loaded with diverse therapeutic cargo (e.g., chemotherapies, nucleic acids, proteins) and specifically targeted to cancer cells. Beyond drug delivery, new data is emerging that HDL-like NPs may be therapeutically active in certain tumor types, for example, B cell lymphoma. Overall, HDL-like NPs are becoming increasingly appreciated as targeted, biocompatible, and efficient therapies for cancer, and may soon become indispensable agents in the cancer therapeutic armamentarium.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25895867      PMCID: PMC4418545          DOI: 10.1007/978-3-319-16555-4_6

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN: 0927-3042


  99 in total

Review 1.  High-density lipoproteins, inflammation and oxidative stress.

Authors:  Fatiha Tabet; Kerry-Anne Rye
Journal:  Clin Sci (Lond)       Date:  2009-01       Impact factor: 6.124

2.  Ligand-coupled lipoprotein for ovarian cancer-specific drug delivery.

Authors:  Ian R Corbin
Journal:  Methods Mol Biol       Date:  2013

3.  Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates.

Authors:  Yizhou Dong; Kevin T Love; J Robert Dorkin; Sasilada Sirirungruang; Yunlong Zhang; Delai Chen; Roman L Bogorad; Hao Yin; Yi Chen; Arturo J Vegas; Christopher A Alabi; Gaurav Sahay; Karsten T Olejnik; Weiheng Wang; Avi Schroeder; Abigail K R Lytton-Jean; Daniel J Siegwart; Akin Akinc; Carmen Barnes; Scott A Barros; Mary Carioto; Kevin Fitzgerald; Julia Hettinger; Varun Kumar; Tatiana I Novobrantseva; June Qin; William Querbes; Victor Koteliansky; Robert Langer; Daniel G Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-10       Impact factor: 11.205

4.  Binding of high density lipoprotein (HDL) and discoidal reconstituted HDL to the HDL receptor scavenger receptor class B type I. Effect of lipid association and APOA-I mutations on receptor binding.

Authors:  K N Liadaki; T Liu; S Xu; B Y Ishida; P N Duchateaux; J P Krieger; J Kane; M Krieger; V I Zannis
Journal:  J Biol Chem       Date:  2000-07-14       Impact factor: 5.157

Review 5.  High-density lipoprotein and atherosclerosis regression: evidence from preclinical and clinical studies.

Authors:  Jonathan E Feig; Bernd Hewing; Jonathan D Smith; Stanley L Hazen; Edward A Fisher
Journal:  Circ Res       Date:  2014-01-03       Impact factor: 17.367

Review 6.  The complex interplay between cholesterol and prostate malignancy.

Authors:  Keith R Solomon; Michael R Freeman
Journal:  Urol Clin North Am       Date:  2011-06-22       Impact factor: 2.241

7.  Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation.

Authors:  T Z Naqvi; P K Shah; P A Ivey; M D Molloy; A M Thomas; S Panicker; A Ahmed; B Cercek; S Kaul
Journal:  Am J Cardiol       Date:  1999-11-01       Impact factor: 2.778

8.  Distribution of high density lipoprotein particles with different apoprotein composition: particles with A-I and A-II and particles with A-I but no A-II.

Authors:  M C Cheung; J J Albers
Journal:  J Lipid Res       Date:  1982-07       Impact factor: 5.922

9.  MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins.

Authors:  Kasey C Vickers; Brian T Palmisano; Bassem M Shoucri; Robert D Shamburek; Alan T Remaley
Journal:  Nat Cell Biol       Date:  2011-03-20       Impact factor: 28.824

10.  Pre-Clinical Evaluation of rHDL Encapsulated Retinoids for the Treatment of Neuroblastoma.

Authors:  Nirupama Sabnis; Suraj Pratap; Irina Akopova; Paul W Bowman; Andras G Lacko
Journal:  Front Pediatr       Date:  2013-03-21       Impact factor: 3.418

View more
  17 in total

1.  Rational Targeting of Cellular Cholesterol in Diffuse Large B-Cell Lymphoma (DLBCL) Enabled by Functional Lipoprotein Nanoparticles: A Therapeutic Strategy Dependent on Cell of Origin.

Authors:  Jonathan S Rink; Shuo Yang; Osman Cen; Tim Taxter; Kaylin M McMahon; Sol Misener; Amir Behdad; Richard Longnecker; Leo I Gordon; C Shad Thaxton
Journal:  Mol Pharm       Date:  2017-10-03       Impact factor: 4.939

2.  Preparation and Characterization of Novel HDL-mimicking Nanoparticles for Nerve Growth Factor Encapsulation.

Authors:  Jing Zhu; Xiaowei Dong
Journal:  J Vis Exp       Date:  2017-05-22       Impact factor: 1.355

3.  Core hydrophobicity tuning of a self-assembled particle results in efficient lipid reduction and favorable organ distribution.

Authors:  Bhabatosh Banik; Ru Wen; Sean Marrache; Anil Kumar; Nagesh Kolishetti; Elizabeth W Howerth; Shanta Dhar
Journal:  Nanoscale       Date:  2017-12-21       Impact factor: 7.790

4.  Mimetic sHDL nanoparticles: A novel drug-delivery strategy to target triple-negative breast cancer.

Authors:  Ton Wang; Chitra Subramanian; Minzhi Yu; Peter T White; Rui Kuai; Jaquelyn Sanchez; James J Moon; Barbara N Timmermann; Anna Schwendeman; Mark S Cohen
Journal:  Surgery       Date:  2019-07-29       Impact factor: 3.982

Review 5.  High-density lipoprotein mimetics: promises and challenges.

Authors:  Dmitri Sviridov; Alan T Remaley
Journal:  Biochem J       Date:  2015-12-15       Impact factor: 3.857

Review 6.  Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases.

Authors:  Christos Tapeinos; Matteo Battaglini; Gianni Ciofani
Journal:  J Control Release       Date:  2017-08-26       Impact factor: 9.776

Review 7.  Targeting the SR-B1 Receptor as a Gateway for Cancer Therapy and Imaging.

Authors:  Linda K Mooberry; Nirupama A Sabnis; Marlyn Panchoo; Bhavani Nagarajan; Andras G Lacko
Journal:  Front Pharmacol       Date:  2016-12-15       Impact factor: 5.810

Review 8.  Nanoparticle-Based Modulation and Monitoring of Antigen-Presenting Cells in Organ Transplantation.

Authors:  Jordi Ochando; Mounia S Braza
Journal:  Front Immunol       Date:  2017-12-22       Impact factor: 7.561

9.  HDL nanoparticles targeting sonic hedgehog subtype medulloblastoma.

Authors:  Jonathan B Bell; Jonathan S Rink; Frank Eckerdt; Jessica Clymer; Stewart Goldman; C Shad Thaxton; Leonidas C Platanias
Journal:  Sci Rep       Date:  2018-01-19       Impact factor: 4.379

Review 10.  HDL as a drug and nucleic acid delivery vehicle.

Authors:  Andras G Lacko; Nirupama A Sabnis; Bhavani Nagarajan; Walter J McConathy
Journal:  Front Pharmacol       Date:  2015-10-26       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.